Activity & Experience
Forest Laboratories has extensive experience partnering with other companies to
develop and market products that make a positive difference in people’s lives. You
can view highlights of our licensees and co-promotion agreements below.
Highlights of Licensees and Co-Promotions (In Order of Most Recent Agreement)
|
Product Brand/Generic
|
Partner
|
Therapeutic Area
|
Stage When Licensed
|
Launch Date
|
Agreement Signed
|
|
Dutogliptin
|
Phenomix
|
Diabetes
|
Phase III
|
In development
|
2008
|
|
NXL-104 (in combination with Ceftaroline Acetate)
|
Novexel
|
Anti-microbial
|
Phase I
|
In development
|
2008
|
|
Linaclotide
|
Ironwood Pharmaceuticals, Inc.
|
Chronic Constipation and Constipation Predominant Irritable Bowel Syndrome
|
Phase IIb
|
In development
|
2007
|
|
Ceftaroline Acetate
|
Cerexa, Inc.*
|
Complicated Skin and Skin Structure Infections and Community Acquired Pneumonia
|
End of Phase II
|
In development
|
2007
|
|
Bystolic®/Nebivolol
|
Mylan Laboratories
|
Hypertension
|
NDA Approvable
|
2008
|
2006
|
|
Aclidinium Bromide
|
Almirall
|
Chronic Obstructive Pulmonary Disorder (COPD)
|
End of Phase II
|
In development
|
2006
|
|
mGLUR1/5
|
Gedeon Richter
|
Anxiety, Depression, and Various CNS Conditions
|
Discovery
|
In development
|
2005
|
|
RGH-896
|
Gedeon Richter
|
Chronic Pain and Various CNS Conditions
|
Phase I
|
In development
|
2005
|
|
Cariprazine
|
Gedeon Richter
|
Schizophrenia and Bipolar
|
Phase I
|
In development
|
2005
|
|
Oglemilast
|
Glenmark Pharmaceuticals
|
Chronic Obstructive Pulmonary Disorder (COPD) and Asthma
|
Preclinical
|
In development
|
2004
|
|
Milnacipran
|
Cypress Bioscience/Pierre Fabre
|
Fibromyalgia
|
End of Phase II
|
In development
|
2004
|
|
Benicar
|
Daiichi Sankyo
|
Hypertension
|
NDA
|
2002
|
2001
|
|
Campral®/acamprosate calcium
|
Merck Santé
|
Alcohol Dependence
|
Phase III
|
2005
|
2001
|
|
Namenda®/memantine
|
Merz
|
Alzheimer’s Disease
|
Beginning of Phase III
|
2004
|
2000
|
Lexapro®/escitalopram
oxalate
|
Lundbeck
|
Major Depressive Disorder, Generalized Anxiety Disorder in Adults
|
Preclinical
|
2002, 2003
|
1998
|
|
Celexa®/citalopram
|
Lundbeck
|
Depression
|
NDA-Ready
|
1998
|
1996
|
*Forest Laboratories completed acquisition of Cerexa, Inc. in 2007
